GSK Invests US$800 million to Open New State-of-the-art Drug Manufacturing Facility in USA
Introduction:
GSK plans to invests US$800 million to open new state-of-the-art facilities for the production of medicines and vaccines in USA.
Features:
The upcoming multi-purpose facility will be equipped to produce sterile liquid vaccines and medicines.
The site will also include a cutting-edge R&D pilot plant to support the production of medicines for clinical trials.
Furthermore, it will introduce a dedicated vaccine drug substance facility designed to manufacture products utilising the innovative MAPS technology, contingent on future regulatory submissions and approvals.
This expansion will significantly increase the size and production capacity of the Marietta site, effectively doubling its current scale.
The new drug product building will integrate advanced technologies such as solar panels, electric heat generation, and systems for water and energy reclamation.
Both facilities will feature intelligent utility and electrical system monitoring, digital twins for ongoing process optimisation, robotics for material handling, and AI-driven predictive maintenance and digital scheduling.
Construction is slated to commence by the end of this year. The drug substance facility is expected to become operational by late 2027, followed by the drug product facility by the end of 2028.
Specifications:
| Name : | GSK |
| Type : | New Construction |
| Budget : | US$800 million |
| Year : | 2028 |
